Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

Video

In Partnership With:

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that led to the FDA approval of palbociclib in combination with letrozole as a first-line treatment for patients with ER-positive, HER2-negative, advanced breast cancer.

Early studies showed that ER-positive, HER2-negative breast cancer models seem to be uniquely sensitive to CDK 4/6 inhibition, Finn notes. Additionally, there was a synergistic inhibition of growth of these models when combined with anti-estrogens.

The global, open-label PALOMA-1 study randomized 165 postmenopausal women with ER-positive, HER2-negative breast cancer to palbociclib with letrozole or letrozole alone. The median progression-free survival (PFS) with palbociclib was 20.2 versus 10.2 months for letrozole alone (HR = 0.49; P = .0004).

In addition to the approval, early results from PALOMA-1 culminated in a breakthrough therapy designation for palbociclib. Following the FDA's decision, palbociclib became the first approved CDK 4/6 inhibitor.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD